1. Introduction {#sec1-molecules-21-01075}
===============

The rhizomes of *Anemarrhena asphodeloides* (Asparagaceae) have been used as traditional Chinese medicine for centuries. Phytochemical studies on *Anemarrhena asphodeloides* have led to the identification of a series of compounds, such as steroidal saponins, flavonoids, phenylpropanoids and alkaloids \[[@B1-molecules-21-01075]\]. The most remarkable of the bioactive ingredients are the steroidal saponins. Recently, steroidal saponin studies were focused on a range of bioactivities, such as anti-inflammatory \[[@B2-molecules-21-01075]\], antiplatelet \[[@B3-molecules-21-01075],[@B4-molecules-21-01075]\], and especially anti-tumor properties \[[@B5-molecules-21-01075],[@B6-molecules-21-01075]\]. To explore its active components, we carried out a series of studies on the rhizomes of *Anemarrhena asphodeloides*. Our experiments have led to the isolations of four new steroidal saponins 1--4, which we have named anemarsaponin P--S, along with four known ones, including anemarsaponin B (**5**) \[[@B7-molecules-21-01075]\], timosaponin D (**6**) \[[@B8-molecules-21-01075]\], timosaponin E1 (**7**) \[[@B9-molecules-21-01075]\], anemarsaponin B II (**8**) \[[@B10-molecules-21-01075]\] ([Figure 1](#molecules-21-01075-f001){ref-type="fig"}).

The cytotoxicity of the isolated compounds has also been evaluated by the MTT method. This paper therefore reports the isolation, structural elucidation, and antiproliferative activities of steroidal saponins from *Anemarrhena asphodeloides*.

2. Results {#sec2-molecules-21-01075}
==========

2.1. Structure Elucidation {#sec2dot1-molecules-21-01075}
--------------------------

Anemarsaponin P (**1**) was obtained as an amorphous power and its molecular formula was C~46~H~76~O~19~ according to the HR-ESI-MS data (*m*/*z* 955.4644 \[M + Na\]^+^) ([Figure S6](#app1-molecules-21-01075){ref-type="app"}). The corresponding ^1^H-NMR ([Figure S7](#app1-molecules-21-01075){ref-type="app"}) data of the aglycone portion ([Table 1](#molecules-21-01075-t001){ref-type="table"}) showed four methyl signals at δ~H~ 0.66 (3H, s), 0.99 (3H, s), 1.73 (3H, s) and 1.12 (3H, d, *J* = 6.8 Hz), three anomeric protons at δ~H~ 4.83 (1H, d, *J* = 8.0 Hz), 5.28 (1H, d, *J* = 7.6 Hz) and 4.92 (1H, d, *J* = 8.0 Hz) and a methoxy group at δ~H~ 3.32 (3H, s). The ^13^C-NMR spectrum ([Figure S8](#app1-molecules-21-01075){ref-type="app"}) showed four methyl groups at δ~C~ 14.6, 24.1, 11.6 and 17.9. Characteristic signals at 109.2 (C-20), 150.4 (C-22) and the secondary carbon signal at δ~C~ 75.5 (C-26) indicated that compound **1** was a Δ^20(22)^-unsaturated furostanol saponin \[[@B11-molecules-21-01075]\]. Comparison of the ^1^H- and ^13^C-NMR spectra in **1** with those of anemarsaponin B (**5**) revealed the ring A--E portions and glycoside moiety of C-3 of the former were consistent with those of **5**. On the other hand, remarkable differences were indicated by the carbon signals from the ring F portion (C-22\~C-27). The HMBC correlations between the methoxy signal (δ~H~ 3.32) and C-23 (δ~C~ 73.7) indicated that methoxy group should be placed in C-23, which was proved by the HMBC correlations from H-24~a~ (δ~H~ 2.07) to C-22 (δ~C~ 150.4) ([Figure 2](#molecules-21-01075-f002){ref-type="fig"}a). The key NOESY correlations between H-23 and H-21/H-27 were indicative of α-orientation for H-23 ([Figure 2](#molecules-21-01075-f002){ref-type="fig"}b). Therefore, the methoxy group at C-23 had a β-orientation. On the basis of above features, a 23*S* configuration was established by reference to notation of *R*,*S*-configuration. The absolute configuration of 25*S* in **1** was established by the chemical shift of H~2~-26 (δ~H~ 3.56 and 4.15 ppm, Δδ = 0.59) (Δδ ≥ 0.57 ppm) \[[@B11-molecules-21-01075]\]. Thus, compound **1** was inferred as (23*S*)-3β,26-dihydroxy-23β-methoxyl-5β-furost-20(22)-en. The absolute configurations of the β-glucose and β-galactose \[[@B12-molecules-21-01075]\] were determined as D by GC analysis of their hydrolyzed forms. The linkage of the sugar in **1** was proved by long-range HMBC correlations between δ~H~ 4.83 (H-1′) and δ~C~ 75.5 (C-26, aglycone), δ~H~ 4.92 (H-1′′) and δ~C~ 75.3 (C-3, aglycone) and δ~H~ 5.28 (H-1′′′) and δ~C~ 81.8 (C-2′′, 3-*O*-β-[d]{.smallcaps}-galactose) ([Figure 2](#molecules-21-01075-f002){ref-type="fig"}a, [Table 2](#molecules-21-01075-t002){ref-type="table"}). Thus, the structure of compound **1** was deduced to be (23*S*,25*S*)-26-*O*-β-[d]{.smallcaps}-glucopyranosyl-3β,26-dihydroxy-23β-methoxyl-5β-furost-20(22)-en-3β-yl-*O*-β-[d]{.smallcaps}-glucopyranosyl-(1→2)-β-[d]{.smallcaps}-galactopyranoside.

Anemarsaponin Q (**2**) was an amorphous power and its molecular formula was C~45~H~74~O~19~ according to HR-ESI-MS at *m*/*z* 941.4714 \[M + Na\]^+^ ([Figure S9](#app1-molecules-21-01075){ref-type="app"}). The ^13^C-NMR spectrum data ([Figure S11](#app1-molecules-21-01075){ref-type="app"}) ([Table 1](#molecules-21-01075-t001){ref-type="table"}) showed four methyl groups at δ~C~ 14.6, 24.0, 11.7 and 17.8. In addition, the carbon signals at δ~C~ 105.1 (C-20), 154.4 (C-22) and the secondary C-26 carbon signal (δ~C~ 75.6) indicated that compound **2** was Δ^20(22)^-unsaturated furostanol saponin \[[@B11-molecules-21-01075]\]. The ^13^C-NMR data of compound **2** was very similar to those of **1**, except for the absence of a methoxy in **2**. Significant differences were observed between **1** and **2** for C-22\~C-27. The C-23 that appeared at δ~C~ 73.7 of **1** was instead an upfield-shifted carbon at δ~C~ 63.9 in compound **2**. The above data suggested that a hydroxy group existed at C-23 of **2**, which was supported by the correlations from H-23 to H-24, H-24 to H-25, and H-25 to H-27 in the ^1^H-^1^H COSY spectrum of **2** ([Figure S1](#app1-molecules-21-01075){ref-type="app"}).

The NOESY cross-peaks between H-23 and H-21 indicated the α-orientation of H-23 and the β-orientation of hydroxyl group for C-23 ([Figure S2](#app1-molecules-21-01075){ref-type="app"}). Being similar to compound **1**, the absolute configuration of 23S was confirmed by reference to the notation of *R*,*S*-configuration. The 25*R* configuration in **2** was proved by the protons of H~2~-26 (δ~H~ 3.81 and 4.07 ppm, Δδ = 0.26) (Δδ ≤ 0.48 ppm) \[[@B11-molecules-21-01075]\]. Compound **2** afforded [d]{.smallcaps}-glucose and [d]{.smallcaps}-galactose, identified by GC analysis of their acid hydrolysis derivatives. Compound **2** was thus established as (23*S*,25*R*)-26-*O*-β-[d]{.smallcaps}-glucopyranosyl-3β,23β,26-trihydroxy-5β-furost-20(22)-en-3β-yl-*O*-β-[d]{.smallcaps}-glucopyranosyl-(1→2)-β-[d]{.smallcaps}-galactopyranoside.

Anemarsaponin R (**3**) ([Figure S12](#app1-molecules-21-01075){ref-type="app"}). had a molecular formula C~45~H~76~O~20~, based on HR-ESI-MS at *m*/*z* 959.4840 \[M + Na\]^+^. In the ^13^C-NMR spectrum ([Figure S14](#app1-molecules-21-01075){ref-type="app"}) of **3** ([Table 1](#molecules-21-01075-t001){ref-type="table"}) four methyl groups (δ~C~ 18.5, 24.7, 16.9 and 17.9) and quaternary carbon (δ~C~ 110.8) suggested that compound **3** was a furostanol saponin \[[@B11-molecules-21-01075]\]. Comparison of ^13^C-NMR data indicated the same skeleton in **3** and timosaponin E1 (**7**). The tiny differences between them were seen in the sugar moiety of C-3. Instead of glucose and galactose in **7**, two glucoses were identified in **3** by the signals at δ~C~ 102.3, 83.6, 78.6, 72.1, 78.7, 63.4 and δ~C~ 106.4, 77.5, 78.4, 72.3, 79.0, 63.2 ([Table 2](#molecules-21-01075-t002){ref-type="table"}). In addition, the existence of glucose was also confirmed by the coupling constant of 9.6 Hz in H-4 for compound **3** instead of the typical one of galactose \[[@B13-molecules-21-01075],[@B14-molecules-21-01075]\]. Meanwhile, the ^13^C-NMR data of the sugar residue matched those of anemarsaponin C \[[@B15-molecules-21-01075]\]. Their sugar linkages were established by the existence of long-range HMBC correlations between δ~H~ 4.81 (H-1′) and δ~C~ 75.9 (C-26, aglycone), δ~H~ 4.94 (H-1′′) and δ~C~ 75.7 (C-3, aglycone) and δ~H~ 5.39 (H-1′′′) and δ~C~ 83.6 (C-2′′, 3-*O*-β-[d]{.smallcaps}-glucose) ([Figure S3](#app1-molecules-21-01075){ref-type="app"}). The sugars of **3** were also only assignable to [d]{.smallcaps}-glucose by GC analysis of their chiral derivatives. The NOESY cross-peaks between the signals of H-23~a~ and H-20, H-15 and H-18 indicated the α-orientations of the hydroxyl groups at C-15 and C-22 ([Figure S4](#app1-molecules-21-01075){ref-type="app"}). In addition, the NOESY correlations between H-3 and H-1′′, H-5 and H-19 indicated the β-orientations of OH-3, H-5 ([Figure S4](#app1-molecules-21-01075){ref-type="app"}). Thus, the structure of compound **3** was established as (25*S*)-26-*O*-β-[d]{.smallcaps}-glucopyranosyl-3β,15α,22α,26-tetrahydroxy-5β-furost-3β-yl-*O*-β-[d]{.smallcaps}-glucopyranosyl-(1→2)-β-[d]{.smallcaps}-glucopyranoside.

Anemarsaponin S (**4**) had a molecular formula C~46~H~76~O~19~, on the basis of HR-ESI-MS at *m*/*z* 779.4193 \[M + Na\]^+^ ([Figure S15](#app1-molecules-21-01075){ref-type="app"}). In the ^1^H-NMR spectrum ([Figure S16](#app1-molecules-21-01075){ref-type="app"}) of **4** ([Table 1](#molecules-21-01075-t001){ref-type="table"}) the signals at δ~H~ 1.08 (3H, s), 1.00 (3H, s), 1.48 (3H, d, *J* = 6.4 Hz) and 1.09 (3H, d, *J* = 6.8 Hz) were assignable to four methyl groups. Correspondingly, the signals at δ~C~ 11.2, 24.0, 14.3 and 16.3 also demonstrated the existences of four methyl groups. In addition, the signal at δ~C~ 110.0 was assignable to the characteristic C-22 carbon signal of a spirostanol saponin. Comparison of the carbon signals revealed multiple similarities between **4** and (25*R*)-5β-spirostane-3β,12β-diol-3-*O*-β-[d]{.smallcaps}-glucopyranosyl-(1→2)-β-[d]{.smallcaps}-galacto-pyranoside \[[@B16-molecules-21-01075]\], excluding the F ring. In the comparison of the F ring signals (δ~C~ 32.2, 29.6, 31.0, 67.2, 17.7), apparent differences were observed at δ~C~ 26.3, 26.5, 27.6, 65.1, 16.3 of **4**. Meanwhile, the ^13^C-NMR data of F ring in **1** were consistent with markogenin 3-*O*-[d]{.smallcaps}-glucopyranosyl-(1→2)-β-[d]{.smallcaps}-galactopyranoside \[[@B17-molecules-21-01075]\]. Certainly, both the shift of H~3~-27 (δ~H~ 1.09, d, *J* = 6.8 Hz) and H~2~-26 proton chemistry shift (δ~H~ 3.40 and 4.13) directly confirmed a 25*S* configuration in **4** \[[@B18-molecules-21-01075]\]. Therefore, compound **4** was formulated as (25*S*)-3β,12β-dihydroxy-5β-spirostane-3β-yl-*O*-β-[d]{.smallcaps}-glucopyranosyl-(1→2)-β-[d]{.smallcaps}-galactopyranoside.

By comparison of NMR data with those reported, the four known compounds were established as anemarsaponin B (**5**) \[[@B7-molecules-21-01075]\], timosaponin D (**6**) \[[@B8-molecules-21-01075]\], timosaponin E1 (**7**) \[[@B9-molecules-21-01075]\], anemarsaponin B II (**8**) \[[@B10-molecules-21-01075]\].

2.3. Cytotoxic Activity {#sec2dot3-molecules-21-01075}
-----------------------

Anemarsaponins P-S (compounds **1**--**4**), anemarsaponin B (**5**), timosaponin D (**6**), timosaponin E1 (**7**) and anemarsaponin B II (**8**) were evaluated for their in vitro cytotoxic activities against two human tumor cell lines (HepG2 and SGC7901) through the MTT method. Among them, anemarsaponin R (**3**) showed medium cytotoxicity against HepG2 cells, with an IC~50~ value of 43.90 μM. Timosaponin E1 (**7**) exhibited medium cytotoxicity against SGC7901 cells, with an IC~50~ value of 57.90 μM. The other compounds did not show significant cytotoxicity (IC~50~ \> 100 μM) ([Table 3](#molecules-21-01075-t003){ref-type="table"}). The dose dependent of cell viabilityon HepG2 (**a**) and SGC7901 (**b**) for compounds ([Figure 3](#molecules-21-01075-f003){ref-type="fig"}).

3. Experimental Section {#sec3-molecules-21-01075}
=======================

3.1. General Experimental Procedures {#sec3dot1-molecules-21-01075}
------------------------------------

Optical rotations were obtained on a P-2000 polarimeter (JASCO, Tokyo, Japan). IR spectra were obtained on a FTIR-8400S instrument (Shimadzu, Kyoto, Japan). UV spectra were obtained on a Shimadzu UV-1601 instrument. NMR spectra were obtained on DPX 400 NMR instrument (Bruker, Rheinstetten, Germany). HR-ESI-MS were recorded on a Xevo-TOF-MS™ instrument (Waters, Milford, MA, USA). HPLC was performed by using a Waters 515 HPLC system coupled with a Waters 2414 refractive index detector. A Waters XBridge preparative C~18~ column (19 × 250 mm, 10 μm) was used. Macroporous absorption resin D-101 (Cangzhou Bon Adsorber Technology Co., Ltd., Cangzhou, China), MPLC (C-610, Büchi, Flawil Switzerland) and ODS silica gel (YMC Ltd., Kyoto, Japan) were used for column chromatography. MeOH and EtOH were analytical grade and purchased from Tian-Jin Fu Yu Co., Ltd. (Tianjin, China). MeCN was HPLC grade and obtained from J&K Scientific Ltd. (Beijing, China).

3.2. Plant Material {#sec3dot2-molecules-21-01075}
-------------------

The rhizomes of *Anemarrhena asphodeloides* Bunge were collected at Bozhou Country, Anhui Province, People's Republic of China, in September 2014, and identified by Ruifeng Fan from Heilongjiang University of Chinese Medicine. A voucher specimen (20140930) has been deposited in the laboratory.

3.3. Extration and Isolation {#sec3dot3-molecules-21-01075}
----------------------------

The dried slice of rhizomes from *Anemarrhena asphodeloides* (56 kg) were extracted three times with hot water (280 L) under reflux. The solutions were combined and evaporated to give a residue (22.09 kg). The crude was suspended with EtOAc, *n*-BuOH, H~2~O, respectively. The *n*-BuOH elute was concentrated under vacuum to yield the *n*-BuOH--soluble fraction.

A part of the fraction (120 g) was chromatographed by MPLC, eluted with a stepwise gradient of MeOH--H~2~O and finally with MeOH, giving 20 subfractions. Fr.5 (3.1 g) was subjected to ODS column chromatography, eluted with a gradient of MeOH--H~2~O (4:6 to 1:0) to yield Fr.5-1\~Fr.5-4. Fr.5-4 (0.8 g) was separated by preparative HPLC (5.0 mL/min, 15% MeCN--H~2~O) and yielded compound **4** (4 mg). Fr.17 (0.2 g) was purified with HPLC (5.0 mL/min, 27% MeCN--H~2~O) to give compound **7** (6 mg). Fr.18 (25 g) was chromatographed over an ODS column to afford Fr.18-1\~Fr.18-5. Compound **5** (2.9 g) was crystallized from Fr.18-3. Fr.18-5 was further purified by HPLC (5.0 mL/min, 30% MeCN--H~2~O) to afford compounds **1** (5 mg), **2** (28 mg) and **3** (8 mg). Fr.19 (2 g) was purified by HPLC (5.0 mL/min, 38% MeCN--H~2~O) to give compounds **6** (7 mg) and **8** (57 mg).

Anemarsaponin P (**1**). White amorphous power; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{21.7}$−67 (*c* 2.0, MeOH); UV (MeOH) γ~max~ 217 nm; CD Δε +1.5 (231 nm); IR (KBr) ν~max~ 3454, 2930, 1646, 1405, 1070 cm^−1^; ^1^H- and ^13^C-NMR data ([Figures S7 and S8](#app1-molecules-21-01075){ref-type="app"}), see [Table 1](#molecules-21-01075-t001){ref-type="table"} and [Table 2](#molecules-21-01075-t002){ref-type="table"}; HR-ESI-MS *m*/*z* 955.4644 \[M + Na\]^+^ (calc. for C~46~H~76~O~19~ 955.4878).

Anemarsaponin Q (**2**). White amorphous power; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{23.2}$−7.1 (*c* 1.7, MeOH); UV (MeOH) γ~max~ 211 nm; CD Δε +1.7 (232 nm); IR (KBr) ν~max~ 2418, 2931, 1067, 1033 cm^−1^; ^1^H- and ^13^C-NMR data ([Figures S10 and S11](#app1-molecules-21-01075){ref-type="app"}), see [Table 1](#molecules-21-01075-t001){ref-type="table"} and [Table 2](#molecules-21-01075-t002){ref-type="table"}; HR-ESI-MS *m*/*z* 941.4714 \[M + Na\]^+^ (calc. for C~45~H~74~O~19~ 941.4722).

Anemarsaponin R (**3**). White amorphous power; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{21.8}$−38.0 (*c* 2.0, MeOH); IR (KBr) ν~max~ 3465, 2935, 1397, 1080 cm^−1^; ^1^Hp and ^13^C-NMR data ([Figures S13 and S14](#app1-molecules-21-01075){ref-type="app"}), see [Table 1](#molecules-21-01075-t001){ref-type="table"} and [Table 2](#molecules-21-01075-t002){ref-type="table"}; HR-ESI-MS *m*/*z* 959.4840 \[M + Na\]^+^ (calc. for C~45~H~76~O~20~ 959.4828).

Anemarsaponin S (**4**). White amorphous power; ${\lbrack\mathsf{\alpha}\rbrack}_{D}^{22}$ −5.0 (*c* 2.0, MeOH); IR (KBr) ν~max~ 3428, 2930, 1397, 1070 cm^−1^; ^1^H- and ^13^C-NMR data ([Figures S16 and S17](#app1-molecules-21-01075){ref-type="app"}), see [Table 1](#molecules-21-01075-t001){ref-type="table"} and [Table 2](#molecules-21-01075-t002){ref-type="table"}; HR-ESI-MS *m*/*z* 779.4193 \[M + H\]^+^ (calc. for C~39~H~64~O~14~ 779.4194).

Anemarsaponin B (**5**). White amorphous power; ^1^H-NMR (400 MHz, Pyridine) δ: 0.70 (3H, s, H-18), 1.00 (3H, s, H-19), 1.64 (3H, s, H-21), 1.04 (3H, d, *J* = 6.4 Hz, H-27), 4.95 (1H, d, *J* = 8.0 Hz, H-1′′), 4.85 (1H, d, *J* = 7.6 Hz, H-1′′′), 5.31 (1H, d, *J* = 7.6 Hz, H-1′); ^13^C-NMR (100 MHz, Pyridine) δ: 31.0 (C-1), 27.0 (C-2), 75.3 (C-3), 31.0 (C-4), 37.0 (C-5), 26.9 (C-6), 26.9 (C-7), 35.2 (C-8), 40.2 (C-9), 35.3 (C-10), 21.3 (C-11), 40.1 (C-12), 43.9 (C-13), 54.8 (C-14), 31.4 (C-15), 84.6 (C-16), 64.7 (C-17), 14.4 (C-18), 24.0 (C-19), 103.6 (C-20), 11.9 (C-21), 152.4 (C-22), 34.5 (C-23), 23.7 (C-24), 33.7 (C-25), 75.3 (C-26), 17.2 (C-27), 102.6 (C-1′′), 82.0 (C-2′′), 77.0 (C-3′′), 69.9 (C-4′′), 76.7 (C-5′′), 62.2 (C-6′′), 106.2 (C-1′′′), 75.6 (C-2′′′), 78.1 (C-3′′′), 71.8 (C-4′′′), 78.5 (C-5′′′), 62.8 (C-6′′′), 105.2 (C-1′), 75.3 (C-2′), 78.6 (C-3′), 71.8 (C-4′), 78.7 (C-5′), 62.9 (C-6′).

Timosaponin D (**6**). White amorphous power; ^1^H-NMR (400 MHz, Pyridine) δ: 0.70 (3H, *s*, H-18), 1.00 (3H, s, H-19), 1.64 (3H, s, H-21), 1.05 (3H, d, *J* = 6.4 Hz, H-27), 4.99 (1H, d, *J* = 7.6 Hz, H-1′′), 4.82 (1H, d, *J* = 7.6 Hz, H-1′′′), 5.28 (1H, d, *J* = 7.6 Hz, H-1′); ^13^C-NMR (100 MHz, Pyridine) δ: 40.1 (C-1), 67.2 (C-2), 82.0 (C-3), 31.9 (C-4), 36.6 (C-5), 26.3 (C-6), 26.9 (C-7), 35.3 (C-8), 41.4 (C-9), 37.1 (C-10), 21.5 (C-11), 40.6 (C-12), 43.8 (C-13), 54.7 (C-14), 31.4 (C-15), 84.6 (C-16), 64.7 (C-17), 14.4 (C-18), 23.9 (C-19), 103.4 (C-20), 11.8 (C-21), 152.4 (C-22), 34.4 (C-23), 23.7 (C-24), 33.7 (C-25), 75.3 (C-26), 17.2 (C-27), 103.6 (C-1′′), 81.8 (C-2′′), 75.3 (C-3′′), 69.8 (C-4′′), 77.0 (C-5′′), 62.1 (C-6′′), 106.2 (C-1′′′), 77.0 (C-2′′′), 78.1 (C-3′′′), 71.8 (C-4′′′), 78.6 (C-5′′′), 62.9 (C-6′′′), 105.2 (C-1′), 75.3 (C-2′), 78.6 (C-3′), 71.8 (C-4′), 78.6 (C-5′), 62.9 (C-6′).

Timosaponin E1 (**7**). White amorphous power; ^1^H-NMR (400 MHz, Pyridine) δ: 0.81 (3H, *s*, H-18), 1.00 (3H, s, H-19), 1.28 (3H, d, *J* = 6.8 Hz, H-21), 1.01 (3H, d, *J* = 6.8 Hz, H-27), 4.81 (1H, d, *J* = 7.6 Hz, H-1′′), 4.96 (1H, d, *J* = 7.6 Hz, H-1′′′), 5.26 (1H, d, *J* = 7.6 Hz, H-1′); ^13^C-NMR (100 MHz, Pyridine) δ: 31.0 (C-1), 27.2 (C-2), 75.5 (C-3), 31.0 (C-4), 37.3 (C-5), 27.0 (C-6), 26.5 (C-7), 36.4 (C-8), 40.5 (C-9), 35.4 (C-10), 21.4 (C-11), 41.3 (C-12), 41.6 (C-13), 60.8 (C-14), 79.1 (C-15), 91.4 (C-16), 61.4 (C-17), 18.0 (C-18), 24.1 (C-19), 40.9 (C-20), 16.5 (C-21), 110.4 (C-22), 37.1 (C-23), 28.4 (C-24), 34.5 (C-25), 75.5 (C-26), 17.5 (C-27), 103.3 (C-1′′), 81.8 (C-2′′), 75.3 (C-3′′), 69.9 (C-4′′), 76.8 (C-5′′), 62.1 (C-6′′), 106.2 (C-1′′′), 77.0 (C-2′′′), 78.1 (C-3′′′), 71.7 (C-4′′′), 78.4 (C-5′′′), 62.9 (C-6′′′), 105.2 (C-1′), 75.3 (C-2′), 78.7 (C-3′), 71.8 (C-4′), 78.5 (C-5′), 62.9 (C-6′).

Anemarsaponin BII (**8**). White amorphous power; ^1^H-NMR (400 MHz, Pyridine) δ: 0.81 (3H, *s*, H-18), 0.99 (3H, s, H-19), 1.32 (3H, d, *J* = 6.8 Hz, H-21), 1.02 (3H, d, *J* = 6.8 Hz, H-27), 4.82 (1H, d, *J* = 8.0 Hz, H-1′′), 4.93 (1H, d, *J* = 7.6 Hz, H-1′′′), 5.30 (1H, d, *J* = 7.6 Hz, H-1′); ^13^C-NMR (100 MHz, Pyridine) δ: 31.4 (C-1), 27.5 (C-2), 75.7 (C-3), 31.4 (C-4), 37.4 (C-5), 27.5 (C-6), 27.3 (C-7), 36.0 (C-8), 40.7 (C-9), 35.7 (C-10), 21.6 (C-11), 40.9 (C-12), 41.7 (C-13), 56.9 (C-14), 32.9 (C-15), 81.7 (C-16), 64.5 (C-17), 17.2 (C-18), 24.5 (C-19), 41.1 (C-20), 17.0 (C-21), 111.1 (C-22), 37.6 (C-23), 28.8 (C-24), 34.9 (C-25), 75.9 (C-26), 17.9 (C-27), 103.0 (C-1′′), 82.3 (C-2′′), 77.4 (C-3′′), 70.3 (C-4′′), 77.1 (C-5′′), 63.2 (C-6′′), 106.6 (C-1′′′), 76.0 (C-2′′′), 78.5 (C-3′′′), 72.2 (C-4′′′), 78.9 (C-5′′′), 63.2 (C-6′′′), 105.6 (C-1′), 75.7 (C-2′), 79.1 (C-3′), 72.2 (C-4′), 79.0 (C-5′), 62.6 (C-6′).

3.4. Acid Hydrolysis and GC Analysis {#sec3dot4-molecules-21-01075}
------------------------------------

The hydrolysis and GC analysis of the four new compounds were carried out for the chiral sugar derivatives. Compounds **1**--**4** (2 mg) were heated with 5 mL 2 M HCl at 90 °C for 3 h. The mixtures were extracted with EtOAc (5 mL) for three times. The sugar residue was dispersed with 1 mL pyridine and reacted with [l]{.smallcaps}-cysteine methyl ester hydrochloride (1.5 mg) at 60 °C for 1 h. Then 150 μL of HMDS-TMCS (hexamethyldisilazane--trimethylchlorosilane, 3:1) was added into the mixture that was further reacted at 60 °C for 30 min. The supernatant of the mixture was evaporated to dryness with a N~2~ stream. The residue was separated with H~2~O (0.1 mL) and *n-*hexane (0.1 mL), and the supernatant layer (1 μL) was analyzed by GC. The configurations of the sugar portion for compounds **1**--**4** were determined by comparison the retention times of their derivatives with those of standard [d]{.smallcaps}-glucose (*t*~R~ = 15.68 min) and [d]{.smallcaps}-galactose (t~R~ = 13.47 min) \[[@B19-molecules-21-01075]\].

3.5. Cytotoxic Activity {#sec3dot5-molecules-21-01075}
-----------------------

The isolated compounds were evaluated for their in vitro antiproliferative activities by the MTT method. Doxorubicin was used as positive control ([Table 3](#molecules-21-01075-t003){ref-type="table"}). Two cell lines, HepG2 and SGC7901, were obtained from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). They were cultured in RPMI 1640 supplemented with 10% FBS, 100 IU/mL penicillin, 100 μg/mL streptomycin in 5% CO~2~ at 37 °C. Cells were cultured in 96-well plates for 24 h with 100 μL complete medium, followed by treating with compounds at different concentrations. 20 μL MTT (5 mg/mL in PBS) was added in the 96-well plates for another 4 h. The solutions were assayed at 490 nm using a VICTOR-X3 ELISA instrument (PerkinElmer, Waltham, MA, USA), after the precipitates were dissolved in DMSO \[[@B20-molecules-21-01075]\]. The cytotoxicities of compounds against HepG2 and SGC7901 were calculated and expressed as IC~50~ values.

4. Conclusions {#sec4-molecules-21-01075}
==============

As described in the introduction, in recent years steroidal saponins have become a research hotspot due to their multiple and strong bioactivities, especially their cytotoxic activities against a series of tumor cell lines \[[@B5-molecules-21-01075],[@B6-molecules-21-01075],[@B21-molecules-21-01075]\]. In this paper, four new saponins were isolated from *Anemarrhena asphodeloides* their strictures elucidated, and their antiproliferative activities against HepG2 and SGC7901 were evaluated. Obvious differences were observed between the antiproliferative activities of compounds **3**, **7** and the others. The above results represent a contribution to the discovery of new active ingredients and lead compounds and provide an experimental and scientific basis for drug design and drug discovery.
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![Structures of compounds **1**--**8** from *Anemarrhena asphodeloides*.](molecules-21-01075-g001){#molecules-21-01075-f001}

![Key HMBC and ^1^H-^1^H COSY correlations (**a**) of compound **1**; Key NOESY correlations (**b**) of compound **1**.](molecules-21-01075-g002){#molecules-21-01075-f002}

![(**a**) Inhibition of HepG2 cell proliferation by the tested compounds; (**b**) Inhibition of SGC7901 cell proliferation by the tested compounds.](molecules-21-01075-g003){#molecules-21-01075-f003}

molecules-21-01075-t001_Table 1

###### 

^1^H-NMR and ^13^C-NMR data for aglycone moiety of compounds **1**--**4** (pyridine-*d*~5~).

  --------------------------------------------------------------------------------------------------------------------------
  No.       1               2       3                     4                                                          
  --------- --------------- ------- --------------------- ------- -------------------- ------- --------------------- -------
  **1a**    1.49 m          31.0    1.48 m                31.0    1.48 ^a^             31.6    1.47 ^a^              31.0

  **1b**    1.87 ^a^                1.83 ^a^                      1.88 ^a^                     1.80 ^a^              

  **2a**    1.21 ^a^        27.0    1.23 ^a^              27.0    1.45 ^a^             27.3    1.51 ^a^              26.7

  **2b**    1.84 ^a^                1.87 ^a^                      1.92 ^a^                     1.95 m                

  **3**     4.28 m          75.3    4.28 m                75.3    4.30 ^a^             75.7    4.31 m                75.5

  **4a**    1.45 ^a^        31.0    1.52 m                31.0    1.80 ^a^             31.2    1.81 ^a^              31.0

  **4b**    1.81 ^a^                1.89 ^a^                      1.82 ^a^                     1.85 ^a^              

  **5**     2.15 m          37.0    2.18 m                37.0    2.20 m               37.4    2.16 m                36.8

  **6a**    0.92 m          26.8    0.98 m                26.9    1.25 ^a^             27.6    1.21 m                27.1

  **6b**    1.82 ^a^                1.20 ^a^                      1.87 ^a^                     1.83 ^a^              

  **7a**    1.51 ^a^                1.51 ^a^                      1.50 ^a^                     0.93 m                

  **7b**    1.98 m          26.9    2.00 m                26.9    2.31 m               27.5    1.28 ^a^              26.7

  **8**     1.38 ^a^        35.1    1.40 ^a^              35.2    1.86 ^a^             36.9    1.54 ^a^              34.7

  **9**     1.22 ^a^        40.2    1.27 ^a^              40.2    1.42 ^a^             40.9    1.46 ^a^              39.4

  **10**                    35.3                          35.3                         35.9                          35.3

  **11a**   1.15 m          21.3    1.15 ^a^              21.3    1.22 ^a^             21.7    1.49 ^a^              31.4

  **11b**   1.32 m                  1.32 m                        1.35 m                       1.78 m                

  **12a**   1.17 ^a^                1.15 ^a^                      1.20 ^a^                                           

  **12b**   1.70 m          40.1    1.72 d (9.2)          40.1    1.68 m               41.6    3.53 dd (4.0, 10.0)   79.5

  **13**                    44.0                          43.9                         41.8                          46.7

  **14**    0.81 m          54.8    0.80 m                54.8    1.53 ^a^             61.4    1.10 m                55.3

  **15a**   1.04 ^a^        34.5    1.42 ^a^              34.5    4.40 ^a^             79.5    1.58 m                31.9

  **15b**   2.05 m                  2.07 dd (5.6, 12.4)                                        2.09 dd (5.4, 12.0)   

  **16**    4.87 m          84.8    4.85 m                84.7    5.05 dd (4, 8.8)     91.9    4.66 t (5.4)          81.4

  **17**    2.55 d (10.0)   65.0    2.50 d (10.4)         65.1    2.18 ^a^             61.9    2.22 ^a^              62.8

  **18**    0.66 s          14.6    0.70 s                14.6    0.95 s               18.5    1.08 s                11.2

  **19**    0.99 s          24.1    0.99 s                24.0    1.04 s               24.7    1.00 s                24.0

  **20**                    109.2                         105.1   2.26 m               41.4    2.18 m                43.6

  **21**    1.73 s          11.6    1.75 s                11.7    1.30 d (6.8)         16.9    1.48 d (6.4)          14.3

  **22**                    150.4                         154.4                        110.8                         110.0

  **23**    4.22 m          73.7    4.92 m                63.9    2.09 ^a^\            37.6    2.18 ^a^\             26.3
                                                                  1.97 m                       1.36 m                

  **24a**   1.87 ^a^        37.3    1.80 br.d (12.4)      39.7    1.70 m               28.9    1.30 m                26.5

  **24b**   2.07 ^a^                2.40 m                        2.07 ^a^                     1.50 ^a^              

  **25**    2.21 m          31.1    2.48 br.d (10.4)      31.0    1.*9*2 ^a^           34.9    1.62 ^a^              27.6

  **26a**   3.56 m          75.5    3.81 br.d (10.4)      75.6    3.48 dd (6.8, 9.2)   75.9    3.40 br.d (10.8)      65.1

  **26b**   4.15 ^a^                4.07 m                        4.08 m                       4.13 m                

  **27**    1.12 d (6.8)    17.9    1.18 d (6.4)          17.8    1.01 d (6.8)         17.9    1.09 d (6.8)          16.3

  OCH~3~    3.32 s          56.0                                                                                     
  --------------------------------------------------------------------------------------------------------------------------

^a^ Overlapped signals.

molecules-21-01075-t002_Table 2

###### 

^1^H-NMR and ^13^C-NMR data for sugar portions of compounds **1**--**4** (pyridine-*d*~5~).

  --------------------------------------------------------------------------------------------------------------------------------------
  No.         1                      2       3                      4                                                            
  ----------- ---------------------- ------- ---------------------- ------- ---------------------- ------- --------------------- -------
  Glc-1       4.83 d (8.0)           105.3   4.89 d (7.6)           105.1   4.81 d (7.6)           105.7                         

  2           4.01 m                 75.3    4.07 ^a^               75.2    4.03 ^a^               75.7                          

  3           3.84 ^a^               78.5    3.97 m                 78.6    4.24 br.d (8.8)        79.1                          

  4           4.20 ^a^               71.7    4.22 t (8.4)           71.8    4.23 br.d (8.8)        72.2                          

  5           4.21 ^a^               78.6    4.24 m                 78.7    3.95 ^a^               78.9                          

  6           4.36 m\                62.9    4.39 dd (2.8, 12.4)\   63.0    4.32 dd (3.2, 14.8)\   63.3                          
              4.45 d (8.0)                   4.55 dd (5.6, 12.4)            4.50 br.d (14.8)                                     

  Gal/Glc-1   4.92 d (8.0)           102.6   4.93 d (7.6)           102.6   4.94 d (7.6)           102.3   4.93 d (8.0)          102.6

  2           4.68 t (7.6)           81.8    4.69 t (11.2)          82.0    4.26 m                 83.6    4.70 ^a^              81.9

  3           4.08 t (7.6)           77.0    4.10 d (11.2)          76.9    4.32^a^                78.6    4.27 dd (3.2, 9.6)    75.3

  4           4.57 dd (2.2, 8.4)     69.9    4.58 ^a^               69.9    4.33 br.d (9.6)        72.3    4.59 d (3.2)          69.9

  5           4.03 ^a^               76.7    4.04 m                 76.6    3.87 m                 78.7    4.03 t (8.4)          76.6

  6           4.43 br.d (9.2)\       62.2    4.40 dd (1.8, 12.0)\   62.2    4.40 d (10.4)\         63.4    4.40 dd (1.2, 8.4)\   62.2
              4.39 dd (3.6, 9.2)             4.45 br. d (12.0)              4.54 br.d (10.4)               4.45 dd (2.4, 8.4)    

  Glc-1       5.28 d (7.6)           106.1   5.30 d (8.0)           106.2   5.39 d (8.0)           106.4   5.30 d (7.6)          106.2

  2           4.35 m                 75.6    4.31 t (8.4)           75.6    4.09 ^a^               77.5    4.10 m                77.0

  3           4.18 ^a^               78.1    4.20 t (8.4)           78.1    4.28 ^a^               78.4    4.22 t (11.2)         78.1

  4           4.30 br.d (9.6)        71.8    4.32 m                 71.9    4.18 br.d (10.0)       72.1    4.34 t (11.2)         71.8

  5           3.84 m                 78.5    3.87 m                 78.4    4.26 ^a^               79.0    3.86 m                78.5

  6           4.53 dd (1.2, 10.8)\   62.9    4.36 dd (4.0, 9.6)\    62.9    4.38 d (8.8)\          63.2    4.47 dd (3.6, 8.4)\   62.8
              4.47 m                         4.48 br.d (9.6)                4.57 br.d (8.8)                4.53 dd (1.2, 8.4)    
  --------------------------------------------------------------------------------------------------------------------------------------

^a^ Overlapped signals.

molecules-21-01075-t003_Table 3

###### 

Cytotoxicities of compounds **1**--**8**.

  Compounds   IC~50~ (μM)    Compounds   IC~50~ (μM)                 
  ----------- -------------- ----------- ------------- ------------- --------------
  **1**       \>100          \>100       **6**         \>100         \>100
  **2**       \>100          \>100       **7**         \>100         57.90 ± 2.88
  **3**       43.90 ± 3.36   \>100       **8**         \>100         \>100
  **4**       \>100          \>100       doxorubicin   8.20 ± 1.25   6.25 ± 2.18
  **5**       \>100          \>100                                   
